Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. (Nasdaq: CUE) on February 12, 2026, reporting an event that occurred on February 9, 2026. The filing addresses a change in the Company's executive leadership structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On February 9, 2026, the Board of Directors appointed Lucinda Warren as Chief Financial and Business Officer, effective immediately. Ms. Warren assumed the duties of the Company's principal financial officer and principal accounting officer. She previously served as Chief Business Officer since September 2024. There are no material changes to her employment agreement or compensation resulting from this appointment.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the appointment. The filing states there are no arrangements or understandings between Ms. Warren and other persons regarding her appointment, no reportable family relationships, and no reportable transactions under Item 404(a) of Regulation S-K. No specific guidance, risks, or contingencies related to financial operations are disclosed in this document.
Key Facts for Investor Verification
- Lucinda Warren is the new Chief Financial and Business Officer, effective February 9, 2026.
- Ms. Warren brings over 30 years of experience in pharmaceuticals and biotechnology, including a decade at Johnson & Johnson.
- Her appointment involves no additional compensation or changes to her existing employment agreement.
- The filing contains no financial data; investors should refer to recent 10-Q or 10-K filings for financial metrics.